Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164891 | 0.78 | CYP2D6 (0.33) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL17541395 | 0.76 | GSK3A (0.31) | — | |
| SCHEMBL23716973 | 0.73 | ALDH1A1 (0.46) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL8629351 | 0.72 | ALDH1A1 (0.42) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL18020563 | 0.70 | SLC1A2 (0.45) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL4147046 | 0.69 | GLA (0.31) | — | |
| SCHEMBL31723977 | 0.67 | LMNA (0.37) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL57078 | 0.66 | KMT2A (0.53) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL1564214 | 0.66 | KMT2A (0.53) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL31259418 | 0.64 | ALDH1A1 (0.46) | ALDH1A1PKMSLC1A2KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011159735-A2 | TETRANOR-PGDM/PGJM SPECIFIC IMMUNOGENS, ANTIBODIES, TRACERS, ASSAY KITS AND METHODS FOR MAKING SAME | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2011-12-22 | — | — | WO | claimed |
| US-20240366712-A1 | GRIFFITHSIN FOR USE IN A METHOD OF PREVENTING OR TREATING INFECTIONS WITH RESPIRATORY VIRUSES | Solmic Biotech GmbH (DE) | 2024-11-07 | — | — | US | disclosed |
| US-20240110220-A1 | DETECTING BETA-LACTAMASE ENZYME ACTIVITY | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2024-04-04 | — | — | US | disclosed |
| CN-117677401-A | Gariferson for use in a method of preventing or treating a respiratory viral infection | 索米克生物技术有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117015613-A | Detection of beta-lactamase activity | 原子能和代替能源委员会 | 2023-11-07 | — | — | CN | disclosed |
| EP-3893937-A2 | HERBOXIDIENE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123836-A2 | HERBOXIDIENE SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-06-18 | — | — | WO | disclosed |
| EP-2150282-B1 | COMPOSITIONS AND METHODS FOR SCAFFOLD FORMATION | REGENTIS BIOMATERIALS LTD (IL) | 2018-04-11 | — | — | EP | disclosed |
| US-20170182214-A1 | COMPOSITIONS AND METHODS FOR SCAFFOLD FORMATION | REGENTIS BIOMATERIALS LTD. (IL) | 2017-06-29 | — | — | US | disclosed |
| US-9624259-B2 | Compositions and methods for scaffold formation | REGENTIS BIOMATERIALS LTD. (IL) | 2017-04-18 | — | — | US | disclosed |
| US-20010044147-A1 | Synthetic biodegradable amphipathic lipids, may include targeting agents | CELL GENESYS, INC. | 2001-11-22 | — | — | US | disclosed |
| US-6270983-B1 | FOR USE IN IMMUNOASSAYS | BIOTEZ BERLIN-BUCH GMBH (DE) | 2001-08-07 | — | — | US | disclosed |
| EP-0833613-A1 | DELIVERY VEHICLES COMPRISING STABLE LIPID/NUCLEIC ACID COMPLEXES | SOMATIX THERAPY CORPORATION (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996037194-A1 | DELIVERY VEHICLES COMPRISING STABLE LIPID/NUCLEIC ACID COMPLEXES | SOMATIX THERAPY CORPORATION (US) | 1996-11-28 | — | — | WO | disclosed |
| US-5567432-A | MEMBRANE ENCAPSULATED BY SYNTHETIC NEUMAMINIC ACID RESIDUE;RETICULOENDOTHELIAL SYSTEM | SDG, INC. | 1996-10-22 | — | — | US | disclosed |
| US-5369006-A | Determination of CK isoenzymes and CK isoforms | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-11-29 | — | — | US | disclosed |
| EP-0366770-B1 | LIPOSOMES COUPLED TO HORMONES | VESTAR INC (US) | 1994-02-09 | — | — | EP | disclosed |
| WO-1993004374-A1 | DETERMINATION OF CREATINE KINASE ISOENZYMES AND CREATINE KINASE ISOFORMS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5080896-A | Adjuvant Coupled to Antigen | AKZO N. V. (NL) | 1992-01-14 | — | — | US | disclosed |
| EP-0367166-A1 | Modified interleukin-2 and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044147-A1 | Synthetic biodegradable amphipathic lipids, may include targeting agents | SGMS2, ABHD16A, PHOSPHO1 | ALDH1A1 4819/4885PKM 2110/4885SLC1A2 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.